HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Cullinan Therapeutics (NASDAQ:CGEM) but has lowered the price target from $29 to $28.
May 16, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Cullinan Therapeutics but has lowered the price target from $29 to $28.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100